NASDAQ · Drug Manufacturers - Specialty & Generic

KMDA (KMDA) Stock

$7.06 +1.00% NASDAQ: KMDA Healthcare

Valuation

MetricValue
Price$7.06
Market Cap$407.32M
P/E Ratio20.54
P/B Ratio1.63
P/S Ratio2.50
EPS (TTM)$0.37
52-Week High$9.35
52-Week Low$6.50
Dividend Yield3.18%

Financials & Margins

MetricValue
ROE8.18%
ROA5.80%
ROCE10.41%
Gross Margin14.36%
Operating Margin14.36%
Net Margin11.18%
Debt/Equity0.04
Current Ratio4.11

Annual Financials (USD)

Metric20212022202320242025
Revenue$104.0M$129.0M$143.0M$161.0M$195.0M
Operating Profit$-1.0M$5.0M$10.0M$20.0M$28.0M
Net Profit$-2.0M$-2.0M$8.0M$14.0M$22.0M
EPS$-0.05$-0.05$0.15$0.25$0.37
Op Margin-0.7%3.5%7.1%12.5%14.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$319.0M$322.0M$355.0M$372.0M$379.0M
Total Liabilities$142.0M$146.0M$111.0M$113.0M$110.0M
Cash$19.0M$34.0M$56.0M$78.0M$75.0M
Borrowings$24.0M$21.0M$9.0M$11.0M$12.0M

Latest News

Kamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual Meeting GlobeNewswire · Jul 13, 2026 Kamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing Laboratory GlobeNewswire · Jun 1, 2026 Kamada Ltd (KMDA) Q1 2026 Earnings Call Highlights: Strategic Growth Amid Shipment Delays GuruFocus.com · May 13, 2026 Kamada (KMDA) Q1 2026 Earnings Transcript Motley Fool · May 13, 2026 Kamada Ltd. Q1 2026 Earnings Call Summary Moby · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$29.0M$4.0M$48.0M$28.0M
Investing Cash Flow$-67.0M$-8.0M$-12.0M$-21.0M$-21.0M
Financing Cash Flow$-1.0M$-6.0M$-17.0M$-13.0M$-6.0M
Net Cash Flow$-52.0M$16.0M$21.0M$23.0M$-3.0M
Free Cash Flow$-13.0M$25.0M$-2.0M$37.0M$17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA8.53
FCF Yield3.48%
Quick Ratio2.28
Interest Coverage28.00
Return 1Y-9.34%
Return 3Y46.94%
Return 5Y36.54%

Ownership

Insiders Held7.20%
Institutions Held48.60%
Institutions Float Held52.36%
Institutional HolderSharesReport Date
Phoenix Financial Ltd.1,654,9522026-03-31
Renaissance Technologies, LLC762,9482026-03-31
Wells Fargo & Company597,2362026-03-31
Acadian Asset Management. LLC371,5582026-03-31
ARK Investment Management, LLC269,5572026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AUNA $5.13 +0.59% 1.70 $379.74M 0.00%
EOLS $6.03 -3.05% -9.25 $397.10M 0.00%
GALTGalectin Therapeutics Inc. $3.33 -4.18% -8.53 $218.97M 0.00%
PRTCPureTech Health plc $16.63 +0.85% -0.58 $404.84M 0.00%
QSI $0.81 +7.87% -1.71 $161.11M 0.00%

About KMDA

KMDA is led by CEO Amir London, employs 420 people, headquartered in IL, publicly traded since 2013.

KMDA stock trades at $7.06 with a market capitalization of $407.32M. The stock is valued at a price-to-earnings (P/E) ratio of 20.54, price-to-book of 1.63, price-to-sales of 2.50. Over the past 52 weeks the stock has ranged between $6.50 and $9.35, and currently trades 24.5% below its 52-week high. It pays a dividend yielding 3.18%.

On profitability, KMDA generates a return on equity (ROE) of 8.18%, return on capital employed of 10.41%, an operating margin of 14.36%, a net profit margin of 11.18%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides